Indivior declares $8.13 per share special dividend tied to Supernus merger closing
The dividend will only be paid if Indivior's pending merger with Supernus Pharmaceuticals closes, expected on or about November 2, 2026.
SEC filing
Latest
7 stories
Thursday, September 17
Monday, August 3
Indivior and Supernus agree to merger of equals
The two CNS-focused drugmakers plan to combine into a single company with about $2.2 billion in pro forma net revenue, targeting a close in the fourth quarter of 2026.
SEC filing
Supernus and Indivior detail merger of equals in August 3 investor presentation
The companies outlined a stock-for-stock combination creating a $2.2 billion CNS company with 11 medicines and targeted cost synergies of at least $125 million.
SEC filing
Supernus and Indivior agree to all-stock merger of equals
The companies will combine into Supernus, Inc., a CNS-focused biopharmaceutical company, with closing expected in the fourth quarter of 2026.
SEC filing
Supernus and Indivior agree to merge as Supernus reports second-quarter growth
Supernus announced a definitive all-stock merger of equals with Indivior on the same day it posted 32% revenue growth and raised full-year guidance.
SEC filing
Indivior and Supernus agree to merge, forming Supernus, Inc.
Indivior will absorb Supernus in a stock-for-stock deal that renames the combined company and pays holders a $1 billion special dividend.
SEC filing
Wednesday, July 22
Supernus sets August 4 date for second-quarter 2026 results
Supernus Pharmaceuticals will report second-quarter 2026 financial and business results after market close on August 4, 2026, followed by a management conference call.
SEC filing